Issues such as drug resistance in TB, incorrect inhaler use in COPD, certain CFTR mutations that do not respond to CFTR modulators in CF, and immune-related side effects in lung cancer therapies further complicate their management [[27], [28], [29]]. The gene discussed is CFTR; the disease is tuberculosis.